KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.
about
Pleiotropic effects of statins in the diseases of the liverEvolving Insights on Metabolism, Autophagy, and Epigenetics in Liver MyofibroblastsStatin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis.Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease.Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapyAtorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.MircoRNA-145 promotes activation of hepatic stellate cells via targeting krüppel-like factor 4New cellular and molecular targets for the treatment of portal hypertension.Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.Novel treatment options for portal hypertension.Sinusoidal communication in liver fibrosis and regeneration.Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension.How to Face Chronic Liver Disease: The Sinusoidal Perspective.Rationale for the use of statins in liver disease.SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis.SP and KLF Transcription Factors in Digestive Physiology and Diseases.Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.RNA-seq analysis of the kidneys of broiler chickens fed diets containing different concentrations of calcium.Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.Advances and challenges in cirrhosis and portal hypertension.Statins in cirrhosis-Ready for prime time.Pretreatment Donors after Circulatory Death with Simvastatin Alleviates Liver Ischemia Reperfusion Injury through a KLF2-Dependent Mechanism in Rat.Statins improve NASH via inhibition of RhoA and Ras.Liver Sinusoidal Endothelial Cell: An Update.Pharmacologic prevention of variceal bleeding and rebleeding.Statins in Cirrhosis: The Magic Pill?Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.Krüppel-like factors: Crippling and un-crippling metabolic pathways.Managing portal hypertension in patients with liver cirrhosis.
P2860
Q26741176-FD1F0998-6CA9-4B77-A034-F1995F8D8357Q26745566-204ED363-F02E-4756-A7A2-C29F04C579D6Q30234533-9270F53B-AA4F-4570-85C7-4D5D54610254Q36030209-09751473-7652-481D-90DE-0C5F52AB97E9Q36505496-CC6BE96E-F7C2-4891-92FA-C42AFAE2B6B7Q36611305-D1D5BDB6-8D26-4EE3-83F6-F341922BBC6FQ37029796-1089F87B-2755-4E78-9837-2CE1539F5D75Q37587636-84409468-B935-402B-AB80-BD67C2528C10Q38383418-D375FBAD-86EB-431A-A425-780DD44374FDQ38656007-667BDDE1-0A59-49E2-BB37-3A35237C6B2BQ38680437-E09277B7-FFCC-41A8-BC77-4E417F708B3EQ38827092-D786BD3D-46F3-436F-BA91-E4F0A466A60CQ38831994-D9B20999-A03A-4781-BDDF-2460FB0ED147Q38940706-0C3F1811-B828-4E0E-A292-7B86539FF931Q39171942-78C7E60B-69D1-44C0-94BD-DAF9C42F5022Q39178715-510F749D-D1EA-47A3-8BE5-1A735B2FF109Q39214035-CD16D561-F274-46CE-A823-7E3F42750F4BQ40285529-9D43BC8E-92A3-42F1-A39E-F9F80A337F3CQ41717850-9228E168-FF80-451D-99C9-B2D5FE8D2BA5Q42206856-CB23962A-3633-4F7F-9B06-7F56232A100CQ47095006-E070CCBB-BF88-404A-A69B-B7D31F152D72Q48097930-2011F39A-C258-4D1C-8BF8-E168A1BD2A10Q48214383-15F65A6F-D34D-4555-A240-596510309253Q48352117-DD3CC49B-0317-416D-8F9B-338D48354F9FQ49612880-2D2C60E4-7AB9-43AE-8365-50B9D39BF2C2Q50054841-1674606F-9979-4A74-A5E1-77812D9AC5FBQ53115134-C72B833D-7673-447E-9F4C-173766E40355Q53817185-694184BB-6D5B-45F7-9057-58DF8631F701Q55079168-8FA0BE92-19F2-492B-A43E-2D756DEAEAF6Q55278061-5B0256D6-2CED-439D-80EB-EB0239B91D97
P2860
KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@en
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@nl
type
label
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@en
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@nl
prefLabel
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@en
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@nl
P2093
P2860
P1433
P1476
KLF2 exerts antifibrotic and v ...... lecular mechanisms of statins.
@en
P2093
Giusi Marrone
Guillermo García-Cardena
Jaime Bosch
Juan G Abraldes
Raquel Maeso-Díaz
P2860
P304
P356
10.1136/GUTJNL-2014-308338
P407
P577
2014-12-10T00:00:00Z